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 Introduction 
 Transmitter release at cortical synapses is controlled 
by an array of presynaptic receptors. These provide a sen-
sitive means of dynamically regulating transmission in a 
synapse-delimited way and, consequently, at the network 
level. In this laboratory, we have been investigating the 
control of both glutamate and GABA release by presyn-
aptic receptors in the entorhinal cortex (EC). This is an 
area of the temporal lobe thought to be pivotally involved 
in processes of learning and memory, but also a site of 
network disruption in epilepsy, schizophrenia and a 
number of other neurological disorders. We have been 
particularly interested in comparing modulation of syn-
aptic activity by auto- and heteroreceptors in neurones of 
the superficial layers of the EC, the main origin of input 
to the adjacent hippocampus, to that in the deeper layers, 
which are the major relay of hippocampal output. For ex-
ample, in slices of rat EC, we have shown that NMDA 
autoreceptors tonically facilitate glutamate release in 
both layer II and layer V [1–3] , but NMDA heterorecep-
tors seem to be present at GABA terminals only in layer 
II [2, 4] . Group III metabotropic glutamate receptors, 
rather surprisingly, increase spontaneous glutamate re-
lease in layer V, but decrease it in layer II [5] . However, 
the same receptors decrease GABA release at inhibitory 
synapses in layer II, but not in layer V [6] . 
 The level of spontaneous GABA release, assessed by 
whole-cell patch-clamp recordings of spontaneous inhib-
itory postsynaptic currents (sIPSCs), is considerably 
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 Abstract 
 Presynaptic GABA B  receptors (GABA B R) control glutamate 
and GABA release at many synapses in the nervous system. 
In the present study we used whole-cell patch-clamp re-
cordings of spontaneous excitatory and inhibitory synaptic 
currents in the presence of TTX to monitor glutamate and 
GABA release from synapses in layer II and V of the rat ento-
rhinal cortex (EC)  in vitro. In both layers the release of both 
transmitters was reduced by application of GABA B R ago-
nists. Quantitatively, the depression of GABA release in layer 
II and layer V, and of glutamate release in layer V was similar, 
but glutamate release in layer II was depressed to a greater 
extent. The data suggest that the same GABA B R may be pres-
ent on both GABA and glutamate terminals in the EC, but 
that the heteroreceptor may show a greater level of expres-
sion in layer II. Studies with GABA B R antagonists suggested 
that neither the auto- nor the heteroreceptor was consis-
tently tonically activated by ambient GABA in the presence 
of TTX. Studies in EC slices from rats made chronically epi-
leptic using a pilocarpine model of temporal lobe epilepsy 
revealed a reduced effectiveness of both auto- and hetero-
receptor function in both layers. This could suggest that en-
hanced glutamate and GABA release in the EC may be asso-
ciated with the development of the epileptic condition. 
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greater in layer II compared to layer V [7] . In a recent 
study   we investigated whether this could be dependent 
on differences in modulation of release by presynaptic 
GABA B  autoreceptors in the two layers [8] . Using the 
GABA B R agonist, baclofen, we found that these receptors 
depressed GABA release in the two layers to around the 
same extent. However, high concentrations of a GABA B R 
antagonist actually increased the release of GABA, sug-
gesting a tonic feedback activation of the autoreceptor. 
The latter effect was restricted to layer V, but was of insuf-
ficient magnitude to fully explain the difference in fre-
quency of sIPSCs recorded in the two layers. 
 In addition to their postsynaptic actions and their role 
as autoreceptors, GABA B R have long been known to act 
as heteroreceptors, controlling the release of a wide vari-
ety of neuroactive agents, including amines, peptides and 
amino acids. In the present study we have examined the 
heteroreceptor control of glutamate release by GABA B R 
in the EC. There has been some debate over whether dif-
ferent subtypes of GABA B R mediate auto- and heterore-
ceptor functions [9–14] . The development of more potent 
and specific GABA B R agonists and antagonists has al-
lowed a more detailed examination of the possibility of 
receptor subtypes at distinct spatial locations. One ago-
nist, CGP44533, has been suggested to be largely inactive 
at postsynaptic receptors [15] , whilst displaying a greater 
potency at heteroreceptors compared to autoreceptors [14, 
16] . We have used this agonist to assess whether there may 
be differences in hetero- and autoreceptors in the EC. 
 The EC has been strongly implicated in the generation 
and propagation of temporal lobe epilepsies [see 4 ], and 
we have been looking at changes in control of transmitter 
release in chronically epileptic animals [e.g.  3 ]. It is ap-
parent    that    mice   that   lack   functional   GABA B R,   either  
 by deletion of the GABA B1  subunit or mutation of the 
GABA B2  subunit, display a phenotype characterized by 
profound tonic-clonic seizure activity [17–19] . GABA B  
autoreceptor function has been shown to be decreased in 
the hippocampus [20, 21]   after electrical kindling, and 
similar changes in heteroreceptors in both hippocam -
 pus and amygdala have also been shown [22–24] . Cur-
rently, there is little information on whether presynaptic 
GABA B R are altered in the EC, although Gloveli et al. [25] 
 reported an enhancement of autoreceptor function in 
layer III in kindled animals. Thus, in the second part of 
the present study, we examined the question of whether 
GABA B R control of either glutamate or GABA release is 
altered in rats with chronic pilocarpine-induced sponta-
neous seizures. Some of the results in this paper have 
been published in abstract form [26] . 
 Methods 
 Slice Preparation 
 Experiments were performed in accordance with the UK An-
imals (Scientific Procedures) Act 1986, European Communities 
Council Directive 1986 (86/609/EEC) and the University of Bath 
ethical review document. Combined entorhinal-hippocampal 
slices were prepared from male Wistar rats, as previously de-
scribed [27] . Rats were anaesthetised with an intramuscular in-
jection of ketamine (120 mg/kg) plus xylazine (8 mg/kg) and de-
capitated. The brain was rapidly removed and immersed in oxy-
genated artificial cerebrospinal fluid (ACSF) chilled to 4  °  C. 
Slices (400   m) were cut using a Vibroslice, and stored in ACSF 
bubbled with 95% O 2 /5% CO 2 , at room temperature. Following 
recovery for at least 1 h, individual slices were transferred to a re-
cording chamber mounted on the stage of an Olympus BX51 mi-
croscope. The chamber was perfused (2 ml/min) with oxygenated 
ACSF (pH 7.4) at 30–32  °  C. The ACSF contained (in m M ): NaCl 
(126), KCl (2.5), NaH 2 PO 4  (1.25), NaHCO 3  (24), MgSO 4  (2), CaCl 2  
(2.5), and  D -glucose (10). Neurones were visualized using differ-
ential interference contrast optics and an infrared video camera. 
 Electrophysiological Recordings 
 Patch pipettes (1–4 M  ) were pulled from borosilicate glass 
on a Flaming/Brown microelectrode puller. For recording EPSCs, 
pipettes were filled with a solution containing (in m M ): Cs-meth-
anosulphonate (120), HEPES (10), QX-314 (5), EGTA (10), CaCl 2  
(0.34), NaCl (4), MgCl 2  (1), ATP-Na (4), and GTP-Na (0.4). IPSCs 
were recorded using a patch pipette solution containing: CsCl 
(120), HEPES (10), QX-314 (5), EGTA (10), CaCl 2  (0.34), MgCl 2  
(1), ATP (4), and GTP (0.4). Solutions were adjusted to 290 mosm, 
and to pH 7.25–7.3 with CsOH. Whole-cell voltage-clamp record-
ings (holding potential –60 mV) were made from neurones in lay-
er V and layer II of the medial division of the EC, using an Axo-
patch 200B amplifier. Series resistance compensation was not em-
ployed, but access resistance (10–30 M  ) was monitored at 
regular intervals throughout each recording and neurones were 
discarded from analysis if it changed by more than  8 10%. Liquid 
junction potentials were estimated using the calculator of pClamp 
8 software, and compensated for in the holding potentials. 
 Under the above recording conditions, EPSCs in both layer II 
and V are mediated by the spontaneous release of glutamate act-
ing at both AMPA and NMDA receptors [28] . No attempt was 
made to distinguish between events mediated by the two recep-
tors, although pure NMDA receptor-mediated events are infre-
quent and most EPSCs reflect the activation of postsynaptic 
AMPA receptors. We did not pharmacologically block GABA A  
receptors in these recordings. However, using the internal and 
external solutions detailed above, all inward currents at the hold-
ing potential of –60 mV could be blocked by a combination of 
NBQX and 2-AP5 [29] . When recording IPSCs, the ACSF rou-
tinely contained NBQX (6-nitro-7-sulphamoylbenzo[f]quinoxal
one-2,3-dione di-sodium; 20   M ) and 2-AP5 ( D,L -2-amino-5-
phosphonovalerate; 50   M ) to block AMPA and NMDA recep-
tors, respectively. Under these recording conditions, i.e. with sim-
ilar concentrations of Cl –  intra- and extracellularly and V h  at –60 
mV, IPSCs are recorded as inward currents, mediated by GABA 
acting at GABA A  receptors [7, 8] . The inclusion of CsCl and QX-
314 in the patch pipette solutions ensured that in all studies, post-
synaptic GABA B R were blocked in the recorded neurones. Spon-
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taneous release at both glutamate and GABA synapses is com-
posed of events driven by action potentials invading  presynaptic 
terminals, and quantal events, which are activity- independent, 
miniature EPSCs (mEPSCs) and mIPSCs. To avoid global net-
work effects of bath-applied drugs, we restricted our studies to 
activity-independent events, and all studies were performed in 
the presence of TTX (1   M ). 
 Data were recorded to computer hard disk using Axoscope 
software. Minianalysis (Synaptosoft, USA) was used for analysis 
of inter-event interval (IEI), amplitude, rise time (10–90%) and 
decay time (to 50%) of mPSCs off-line. Frequencies of events were 
determined as reciprocal of IEI. mPSCs were detected automati-
cally using a threshold-crossing algorithm. Threshold varied 
from neurone to neurone but was always maintained at a constant 
level in any given recording. At least 200 events were sampled dur-
ing a continuous recording period for each neurone under each 
condition. To compare pooled data under control and drug condi-
tions, we determined mean values of parameters of mPSCs in 
each cell and calculated the fractional changes before and after 
drug applications (e.g. the mean frequency in the presence of 
CGP44533 as a fraction of that in TTX alone). All error values 
stated in the text refer to standard error of the mean. We also as-
sessed the significance of shifts in cumulative probability distri-
butions of pooled data using the non-parametric Kolmogorov-
Smirnov test. Student’s t test and one-way ANOVA were used to 
assess differences in fractional changes before and after drug ap-
plication. 
 Chronically Epileptic Animals 
 Initial experiments to determine the effects of GABA B  ago-
nists and antagonists were performed in slices taken from juvenile 
animals (4–6 weeks). In studies comparing chronically epileptic 
rats with age-matched controls, the animals were aged 4–6 months 
at the time of electrophysiological experiments. 
 Rats were rendered chronically epileptic using a modified ver-
sion of the pilocarpine model described by Glien et al.  [30] . They 
were pretreated with LiCl (200–300 mg/kg i.p.). Twenty-four 
hours later they received   -methyl scopolamine (1 mg/kg i.p.) to 
block the peripheral cholinergic effects of pilocarpine, and 15 min 
later received pilocarpine, administered in very low doses (5–
10 mg/kg i.p.) repeated as necessary (up to a maximum of 40 mg/
kg) at 30-min intervals until an acute status epilepticus (SE) was 
induced. After induction of SE, animals were administered the 
central muscle relaxant, xylazine (4 mg/kg i.m.), which reduced 
the severity of clonic contractions without preventing electrical 
seizure activity. After 1.5 h in SE, seizures were terminated with 
diazepam (10 mg/kg i.p.). When necessary they were orally ad-
ministered glucose in normal saline for rehydration on the day of 
the SE and on the subsequent 2–3 days. Using this modified ap-
proach, we achieved a mortality rate of around 5–10%, and devel-
opment of spontaneous recurrent seizures in 100% of animals. 
Age-matched control animals received the initial injection of 
LiCl, but nothing else. 
 Following the acute SE, animals developed evidence of epilep-
tic seizure activity during a latent period of 6–10 weeks. This in-
cluded the appearance of occasional head twitches, wet dog 
shakes, forepaw clonus, oro-facial movements and whole body 
jerks. Eventually, all animals began to display spontaneous recur-
rent seizures, which were characterized by rearing plus loss of 
balance, and accompanied by generalized clonic seizures. The li-
censing of our chronic experiments required that the animals be 
used for electrophysiology as soon as possible after developing 
chronic seizures. In practice this meant that most animals were 
used within 2 weeks after the first seizure was noted, up to a max-
imum of 4 weeks. Because animals were used as soon as possible, 
it was not possible to correlate adaptive changes with baseline sei-
zure frequency. 
 Materials 
 Salts used in preparation of ACSF were ‘Analar’ grade and pur-
chased from Merck/BDH (UK). All drugs were applied by bath 
perfusion. NBQX and 2-AP5 were obtained from Tocris (UK), 
GABA B R agonists (CGP44533 and CGP35024) and antagonists 
(CGP55845 and CGP64213) were a kind gift from Novartis Phar-
ma (Basel, Switzerland), and TTX was supplied by Alamone Lab-
oratories (Jerusalem, Israel). Concentration-response curves to 
agonists were constructed cumulatively, with each concentration 
being applied for a 10-min period. When the effects of antagonists 
were tested, after establishing control responses to agonists, the 
antagonists were perfused for at least 15 min, before re-testing of 
agonists. 
 Results 
 Preliminary experiments determined that activation 
of GABA B R with either baclofen (3   M ) or CGP44533 
(3   M ) reduced the frequency of sEPSCs in both layer II 
and layer V neurones without changing amplitude, in-
dicative of a presynaptic depression of glutamate release 
[M.O. Cunningham, PhD thesis, unpubl. results]. All 
subsequent studies, described below, were made in the 
presence of TTX to isolate activity-independent release 
and rule out network effects of GABA B R activation. The 
experiments described were conducted on 67 neurones in 
layer II and 74 neurones in layer V of the medial EC. In a 
representative sample of neurones in the two layers the 
mean IEI was 296.3  8 47.5 ms in layer V (n = 27) and 
151.1  8 20.5 ms in layer II (n = 30), reflecting average 
frequencies of around 3.5 and 6.6 Hz, respectively. Cor-
responding mean amplitudes were 9.7  8 0.9 and 9.0  8 
0.8 pA. 
 Effects of GABA B R Agonists on mEPSCs 
 The effect of GABA B R agonist, CGP44533, was tested 
at concentrations from 10 n M to 25   M on a total of 37 
neurones in layer II and 44 in layer V. The drug caused a 
robust and reversible decrease in frequency of mEPSCs 
in both layers.  Figure 1 a illustrates this effect in one neu-
rone recorded in layer II. The mean IEI in the control 
situation was 176  8 4 ms. During perfusion with 
CGP44533 (0.5   M ) this increased to 259  8 6.8 ms. Sub-
sequent addition of the agonist at 1, 5 and 10   M resulted 
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in increments in IEI to 389  8 16, 897  8 41 and 1,040  8 
52 ms, respectively. These changes reflect a concentra-
tion-dependent decrease in average instantaneous fre-
quency from 5.7 Hz to 3.9, 2.6, 1.1 and 0.9 Hz over the 
range of concentrations tested.  Figure 1 b shows cumula-
tive probability distributions of pooled IEI data for 1 (n = 
12), 5 (n = 12) and 10   M (n = 15) CGP44533. The sub-
stantial shift of these distributions to the right reflects the 
decreasing frequency of events and the change was high-
ly significant at all concentrations (Kolmogorov-Smirnov 
test, p  1 0.001). There was no change in amplitude of 
events at any concentration tested. In the presence of 
a
Control
CGP44533 0.5 µM  
1 µM
5 µM
10 µM
Wash
500 ms
10
 p
A
C
um
ul
at
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1
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C
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ul
at
iv
e 
p
ro
b
ab
ili
ty
IEI (ms)
b
c
Control
1 µM
5 µM
10 µM
Control
1 µM
5 µM
10 µM
 Fig. 1. Presynaptic GABA B R reduce glutamate release.  a Whole-cell voltage-clamp recordings from a layer II 
neurone. The control trace shows mEPSCs recorded in the presence of TTX. The records below show the re-
duced frequency of mEPSCs in the presence of cumulative applications of CGP44533 at increasing concentra-
tions, followed by recovery on washing.  b The graphs show cumulative probability relationships of pooled data 
from neurones in layer II (n = 5) for inter-event interval (IEI) at three concentrations of CGP44533. The pro-
gressive shifts to the right illustrate the prolongations of IEI reflecting the reduced frequencies of events.  c The 
cumulative probability data distributions for layer V neurones (n = 5) show less shift to the right, illustrating 
the reduced effectiveness of the agonist in this layer. 
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TTX alone the mean amplitude of events was 9.5  8 0.3 
pA, and with the subsequent application of increasing 
concentrations of CGP44533, the corresponding mean 
values were 9.5  8 0.3, 9.5  8 0.3, 10.4  8 0.4 and 9.4  8 
0.3 pA. Likewise, neither rise nor decay times of events 
were altered by the agonist. The mean control rise time 
was 3.3  8 0.5 ms and the respective values in the pres-
ence of the four agonist concentrations were 3.6  8 0.6, 
3.1  8 0.2, 3.7  8 0.6 and 3.7  8 0.3 ms. Corresponding 
values for decay times were 5.2  8 0.7 ms (control), 6.4  8 
0.8 (0.5   M ), 5.7  8 0.7 (1   M ), 6.1  8 0.5 (5   M ) and 6.0 
 8 0.4 (10   M ). 
 CGP44533 also reduced the frequency of mEPSCs 
without affecting the amplitude in layer V neurones. Cu-
mulative probability curves for pooled IEI data are shown 
for 1, 5 and 10   M concentrations of the agonist in  fig-
ure 1 c. The mean control IEI was 247  8 8 ms. CGP44533 
(0.5   M ) increased this to 289  8 10 ms. At 1, 5 and 10   M 
the agonist resulted in increments in IEI to 339  8 25, 640 
 8 63 and 739  8 88 ms, respectively. These changes re-
flect a decrease in instantaneous frequency from 4.1 Hz 
to 3.5, 2.9, 1.6 and 1.4 Hz over the concentrations tested 
and indicate that the drug may be less effective at reduc-
ing mEPSC frequency in layer V compared to the layer II. 
However, as in layer II, the agonist had no effect on 
 amplitude ( table 1 ), rise or decay time of events (not 
shown). 
 A more detailed comparison of the effect of the agonist 
in the two layers is illustrated by the pooled data from all 
cells shown in  figure 2 . When the fractional reduction in 
mEPSC frequency is plotted against concentration 
( fig. 2 a), the curve for layer V is shifted to the right of that 
for layer II, suggesting that the activation of the GABA B  
heteroreceptor is more effective at reducing glutamate re-
lease at synapses in the superficial layer. The divergence 
between the effect in the two layers increases with in-
creasing concentration. The difference was significant at 
5, 10 and 25   M (t test, p  ! 0.01) but not at lower concen-
trations. Thus, the depression of mEPSC frequency was 
maximal with 10–25   M CGP44533 in both layers, but 
the maximal depression was greater in layer II than in 
layer V.  Figure 2 b shows the concentration-response data 
normalized to the maximum depression of frequency. 
EC 50  values determined from these data were virtually 
the same (0.79   M in layer II and 0.91   M in layer V). The 
fractional frequencies and amplitudes for the data illus-
trated in  figure 2 b are shown in  table 1 . 
 We have tested the effect of a second agonist, CGP35024 
(0.1–10   M ), on a total of 16 neurones in layer II and 14 in 
layer V. A similar picture emerged, with the drug being 
more effective in reducing mEPSC frequency in the su-
perficial compared to the deep layer. Additionally, the 
concentration-response relationships in each layer were 
shifted a little to the left with respect to CGP44533. In 
layer II, fractional mEPSC frequencies for CGP35024
at 1 and 5   M were 0.48  8 0.04 (n = 8) and 0.20  8 0.05 
(n = 4) compared to 0.53  8 0.05 (n = 12) and 0.25  8 0.3 
(n    =    12)   for   CGP44533.   Corresponding   values   in   layer  
 V    were    0.58    8    0.06    (n    =    5)    and    0.31    8   0.07   (n   =   3)  
 for    CGP35028,  and   0.63   8   0.05   (n   =   14)   and   0.38   8  
 0.04 (n = 13) for CGP44533. Estimated EC 50  values for 
CGP35028 in layer II and layer V were 0.64 and 0.73   M , 
CGP44533
M
Layer II mEPSCs Layer V mEPSCs
fractional
frequency
fractional
amplitude
n fractional
frequency
fractional
amplitude
n
0.01 0.8980.08 1.0780.07 4 0.9180.01 0.9680.04 9
0.1 0.7680.07 0.9180.10 3 0.8380.01 0.9980.06 7
0.5 0.6780.05 0.9980.09 14 0.7680.05 0.9780.05 14
1 0.5380.05 0.9980.48 12 0.6380.05 1.0180.02 14
2 0.3980.05 1.0180.02 9 0.4880.06 0.9980.07 10
5 0.2580.03 1.1180.10 12 0.3880.04 0.9880.05 13
10 0.1780.03 0.9480.04 15 0.2980.04 0.9980.08 15
25 0.1780.02 1.0080.06 8 0.2980.05 0.9580.09 11
Frequencies of events were calculated from IEI and fractional frequencies at each 
concentration represent the frequency in the presence of the drug as a fraction of that in 
the presence of TTX alone.
 Table 1. Concentration-dependent effect 
of CGP44533 on mEPSCs in EC 
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respectively. Again, CGP35028 had no significant effect 
on amplitude of mEPSCs in either layer (data not shown). 
In layer V the mean control amplitude was 8.2  8 1.2 pA, 
9.6  8 2.5 pA at 1   M , and 8.4  8 2.3 pA at 5   M . In layer 
II, the fractional amplitude of events in the presence of 
the agonist were 0.91  8 0.4 and 1.06  8 0.03 at 1 and 
5   M , respectively, and 1.06  8 0.12 and 1.03  8 0.11 in 
layer V. 
 Effects of GABA B R Antagonists on mEPSCs 
 The reduction in frequency of mEPSCs by CGP44533 
(10   M ) was completely blocked by pre-perfusion with 
the GABA B R antagonist, CGP64213 (10   M ) in both lay-
er V (n = 3) and layer II (n = 3). In layer II, the fractional 
frequency of mEPSCs was 0.18  8 0.03 in the presence of 
the agonist alone and 1.04  8 0.02 when the antagonist 
was present. In layer V, the corresponding values were 
0.30  8 0.03 and 0.98  8 0.06. Another GABA B R antago-
nist (CGP55845, 5   M ) also abolished the effects of 
CGP44533 (not shown). In the presence of the antago-
nists alone, occasional neurones showed a tendency to-
wards an increase in frequency of mEPSCs, but overall 
there was no significant effect on either frequency or am-
plitude in either layer. The results of these studies are 
summarized in  table 2 . 
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Antagonist
M
Layer II mEPSCs Layer V mEPSCs
fractional 
frequency
fractional
amplitude
n fractional
frequency
fractional
amplitude
n
CGP55845 (5) 1.0380.06 1.0380.14 5 1.1180.25 0.9680.12 3
CGP64213 (10) 1.0180.01 0.9880.19 16 1.0080.03 0.9980.06 13
Neither drug had any effect on frequency or amplitude of events.
 Table 2. Effect of GABA B R antagonists 
on mEPSCs 
 Fig. 2. Concentration-response data for the reduction in mEPSC 
frequency by CGP44533 in layer V and layer II neurones.  a Data 
plotted as fractional reduction in frequency against concentration 
show that the GABA B R agonist was consistently less effective at 
reducing mEPSC frequency in layer V compared to layer II. The 
difference was significant from 10–25   M , where it is clear that 
there is a reduced maximal effect in the deep layer. Figures in pa-
rentheses are the numbers of neurones tested at each concentra-
tion.  b When the data are normalised to the maximal depression 
in frequency, the curves are closely superimposed. 
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 Effect of CGP44533 on mIPSCs 
 We have previously described depression of mIPSC 
frequency by baclofen in the EC [8] . In the present studies 
we have compared the effect of CGP44533 on mIPSCs in 
layer II and layer V to those described above for mEPSCs. 
In a typical sample of layer V neurones (n = 10) mIPSCs 
had an IEI of 325  8 46 ms and amplitude of 18.8  8 2.4 
pA. Rise and decay times were 2.8  8 0.2 and 6.9  8 0.9 
ms, respectively. Corresponding mean values in layer II 
neurones (n = 10) were 29  8 4 ms (IEI), 19.2  8 1.4 pA 
(amplitude), 2.5  8 0.1 ms (rise) and 7.5  8 0.4 ms (decay). 
The only difference lay in the frequency of events, which 
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 Fig. 3. Presynaptic GABA B R reduce GABA release.  a Voltage-clamp recordings of mIPSCs in a layer II neurone 
(TTX present throughout). CGP44533 substantially reduced the frequency of events. The cumulative probabil-
ity curves show pooled data from 15 neurones with two concentrations of the agonist. The shifts of the curves 
to the right illustrate the concentration dependent increase in IEI.  b Similar data for layer V neurones (n = 
15). 
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was much higher in layer II (approx. 34 Hz) than in layer 
V (3 Hz), as we previously described [7] . For the purpos-
es of comparison of the effects of CGP44533, we used con-
centrations that were intermediate (3   M ) and essentially 
maximal (10   M ) for effects on mEPSCs. 
 The records in  figure 3 a show a strong reduction in 
mIPSC frequency by CGP44533 (10   M ) in an individual 
layer II neurone and the cumulative probability curves 
represent pooled data at the two concentrations tested 
(n = 15 in each case). The shift to the right of the IEI dis-
tributions in the presence of the agonist reflects a concen-
tration-dependent reduction in mIPSC frequency.  Fig-
ure 3 b shows data from layer V neurones (n = 15 at each 
concentration), and illustrates that the agonist had very 
similar effects to that seen in layer II. In layer V the mean 
IEI was increased from 569  8 59 to 1,146  8 184 ms in 
the presence of 5   M CGP44533, and further to 1,863  8 
366 ms when 10   M was added. In layer II, the control IEI 
was 140  8 35 ms and this increased to 289  8 58 and 536 
 8 87 ms in the presence of the two agonist concentra-
tions. The mean fractional mIPSC frequencies in the two 
layers reflect these changes ( table 3 ). Amplitudes of 
mIPSCs were unaffected by the agonist in either layer 
( table 3 ) and likewise no changes in rise or decay times 
were observed (not shown). 
 Figure 4 shows a quantitative comparison of the effects 
of CGP44533 on mEPSCs and mIPSCs in the two layers. 
At both 3 and 10   M , the agonist induced a similar de-
pression of mIPSC frequency in layer II and layer V. The 
depression of mEPSC frequency was quantitatively simi-
lar to that of mIPSCs in layer V, but that induced in layer 
II was significantly greater (p  ! 0.05) at both agonist con-
centrations. Thus, there was a differential effect of 
CGP44533 at excitatory terminals in layer V compared to 
layer II and compared to inhibitory terminals in both lay-
ers. 
 Effects of Antagonists on mIPSCs 
 As with mEPSCs, the reduction in frequency of 
 mIPSCs by CGP44533 was abolished by a GABA B R an-
tagonist. In layer II the fractional frequency in the pres-
ence of the CGP44533 alone (10   M ) was 0.35  8 0.05, but 
when applied together with CGP55845 (5   M ) it was 1.06 
Fr
ac
ti
on
al
 P
SC
 fr
eq
ue
n
cy
0
mIPSC layer V 
mIPSC layer II  
mEPSC layer V 
mEPSC layer II  
0.25
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 Fig. 4. Summary data for the effects of CGP44533 on mPSC fre-
quency. The columns represent the mean fractional frequencies 
of events in 3   M (left) and 10   M of the agonist and the errors are 
standard error of the mean. Quantitatively, the only difference 
was a significantly greater reduction in mEPSC frequency in lay-
er II, which was seen at both concentrations. The degree of reduc-
tion of mEPSCs in layer V and mIPSCs in both layers was similar. 
n = 15 in all cases except for mEPSCs in layer II (n = 13) and layer 
V (n = 10). 
CGP44533
M
Layer II mIPSCs Layer V mIPSCs
fractional
frequency
fractional
amplitude
n fractional
frequency
fractional
amplitude
n
3 0.5480.06 1.0480.06 15 0.5680.06 0.9780.06 15
10 0.3580.05 0.9480.08 15 0.4080.05 0.9880.04 15
Neither drug had any effect on frequency or amplitude of events. Frequencies of 
events were decreased to about the same extent in the two layers, and amplitudes were 
unaltered.
 Table 3. Effect of CGP44533 on mIPSCs 
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 8 0.06 (n = 3). Likewise, in three neurones in layer V the 
corresponding values were 0.40  8 0.04 and 0.97  8 0.04, 
respectively. 
 CGP55845 alone had no significant effect on mIPSC 
frequency, amplitude, rise or decay times. Fractional fre-
quencies in the presence of CGP55845 were 1.02  8 0.06 
in layer II (n = 5) and 1.11  8 0.25 in layer V (n = 6). As 
was the case with mEPSCs, occasional neurones did show 
quite a clear and consistent increase in frequency when 
CGP55845 was applied, particularly in layer V, but most 
showed no effect, or minor increases or decreases in fre-
quency.   Also,   CGP64213   (10    M )   had   no   effect on 
 mIPSCs in either layer II (1.01  8 0.01, n = 16) or layer V 
(1.0  8 0.03, n = 10). 
 GABA B R Function in Epileptic Animals 
 There are some changes in the frequency and charac-
teristics of mEPSCs and mIPSCs associated with the de-
velopment of the chronic epileptic condition. Some of 
these have been described briefly elsewhere [31–33] . De-
tailed accounts of these changes are beyond the scope of 
the current paper, and are currently in preparation [G. 
Ayman, G.L. Woodhall and R.S.G. Jones, unpubl. re-
sults]. Generally, data in a large population of neurones 
indicate a slightly increased frequency of mEPSCs in 
both layers, accompanied by a small increase in ampli-
tude and a slowing of both rise and decay times, but it 
should be stressed that none of the differences are pro-
nounced. mIPSCs, in contrast to mEPSCs, show a de-
creased frequency in epileptic animals, but amplitudes 
were also concurrently increased. Rise times of mIPSCs 
are generally unaltered but decay times, in both layers, 
are prolonged. These data indicate that there may be pre- 
and postsynaptic changes in both excitation and inhibi-
tion in the epileptic EC, but that these changes, at least 
assessed by means of spontaneous synaptic currents, are 
not dramatic and there is considerable overlap and varia-
tion. Thus, in the smaller samples of cells studied below, 
the differences noted in our larger population of data are 
not necessarily reflected. 
 Effects of CGP44533 on mEPSCs in Epileptic Animals 
 Perfusion with CGP44533, produced a similar depres-
sion of mEPSC frequency in older age-matched (AM) 
control animals to that seen in juvenile animals (see 
above). However, when tested on mEPSCs in slices from 
epileptic animals, the drug was considerably less effec-
tive. For example, in 5 layer II neurones in AM control 
slices a mean IEI of 143  8 20 ms was increased to 462  8 
84 ms in the presence of CGP44533 at 10   M , equating to 
a mean fractional frequency of 0.33  8 0.07. In corre-
sponding studies in epileptic slices, the IEI was increased 
from 169  8 45 to 333  8 71 ms by CGP44533 at 10   M , 
giving a fractional frequency of 0.66  8 0.11 (n = 7). The 
mean amplitude of events in AM control slices, as in ju-
venile slices, was unaltered by CGP44533 (12.4  8 0.9 vs. 
11.9  8 0.7 pA), and this was the same in epileptic slices 
(13.1  8 1.8 vs. 12.0  8 1.7 pA). Likewise, rise times (AM 
control 1.6  8 0.2 vs. 1.5  8 0.1 ms; epileptic 2.8  8 0.6 vs. 
3.0  8 0.7 ms) and decay times (AM control 2.2  8 0.2 vs. 
2.0  8 0.1 ms; epileptic 3.2  8 0.3 vs. 3.1  8 0.4 ms) of 
events were unaltered by the agonist in either group. 
These results were mirrored by those with the lower con-
centration (3   M ) of CGP44533 in layer II. The fractional 
frequency of mEPSCs in these studies was 0.63  8 0.11 
(n = 4) in AM control slices but only 0.81  8 0.17 (n = 6) 
in layer II neurones recorded in slices from epileptic ani-
mals. Thus, these data reflect a considerable reduction in 
the effectiveness of the GABA B R agonist at depressing 
mEPSC frequency. Very similar results were seen in layer 
V neurones and the results of changes in frequency for 
both layer II and layer V are summarized by the bar 
graphs in  figure 5 a. Again, as in layer II, the amplitudes 
rise and decay times of mEPSCs in layer V were unaf-
fected by CGP44533 in slices from AM control or epilep-
tic animals. 
 Effects of CGP44533 on mIPSCs in Ipileptic Animals 
 mIPSCs showed a similar change in sensitivity to 
CGP44533 as mEPSCs in neurones recorded in slices 
from epileptic animals. Thus, the depression in frequency 
of mIPSCs by the GABA B R agonist was less marked com-
pared to that seen in control slices, in both layer V and 
layer II. The data for layer V neurones with CGP44533 at 
10   M are representative. In AM control slices, the ago-
nist increased mean IEI to 400  8 49 from 133  8 19 ms, 
representing a fractional frequency of 0.36  8 0.03 in the 
presence of the drug. In contrast, in neurones (n = 5) in 
epileptic slices the mean IEI was 103  8 35 ms before the 
drug was applied and increased to 159  8 88 ms in its 
presence, a fractional frequency of 0.63  8 0.12. Ampli-
tudes of mIPSCs were unaltered in either AM control 
(13.9  8 2.8 vs. 15.1  8 3.1 pA) or epileptic slices (21.9  8 
4.3 vs. 20.1  8 2.9 pA). As with mEPSCs, neither rise times 
(AM control 2.5  8 0.3 vs. 2.2  8 0.3 ms: epileptic 2.4  8 
0.4 vs. 2.8  8 0.5 ms) nor decay times (AM control 5.3  8 
1.5 vs. 5.4  8 1.4 ms; epileptic 7.7  8 2.5 vs. 6.9  8 3.4 ms) 
were altered by the agonist. The data on frequency chang-
es together with those for a lower dose of the agonist, and 
also for layer II neurones, are summarized in  figure 5 b. 
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 Effects of GABA B R Antagonists in Epileptic Animals 
 Finally, we examined the effects of a GABA B R antago-
nist alone on mEPSCs and mIPSCs in AM control and 
epileptic rats. CGP55845 (1 and 5   M ) had little discern-
ible effect on the frequency or amplitude of either cur-
rent, in either layer and in either experimental group. 
Thus, in layer II neurones fractional mEPSC frequencies 
in the presence of the antagonist (at 5   M ) were 0.99  8 
0.08 in control neurones (n = 5) and 0.94  8 0.12 in epi-
leptics (n = 6). In layer V the corresponding values were 
1.12  8 0.04 (n = 4) and 0.97  8 0.04 (n = 4). Effects on 
mIPSCs were more variable, but there were no significant 
differences detected. In layer II, the fractional frequency 
was 1.04  8 0.06 in controls (n = 4) and 1.24  8 0.29 in 
epileptics (n = 6), and in layer V the respective values were 
1.12  8 0.07 (n = 3) and 0.95  8 0.10 (n = 5). 
 Discussion 
 Using the GABA B R agonist, baclofen, we have shown 
previously that spontaneous release of GABA at synapses 
in both deep and superficial layers of the EC can be de-
pressed via the activation of a GABA B  autoreceptor [8] 
with baclofen. We have now confirmed these observa-
tions with a second agonist, CGP44533, which induced a 
similar depression of GABA release. In terms of the per-
centage reduction in mIPSC frequency, this was similar 
in layer V and layer II. This suggests that there is probably 
a single GABA B R responsible for control of GABA release 
in the deep and superficial layers, or that CGP44533 can-
not discriminate between different receptors present in 
the two layers. The mechanism of the autoreceptor effect 
remains unknown. We have shown that the depression of 
release applies not only to activity driven release [8] but, 
like others [34–36] , to quantal release occurring in the 
absence of spontaneous action potentials also. The latter 
effect is unlikely to be related to the established action of 
GABA B R on GIRKs [37, 38] or voltage-gated calcium 
channels [39, 40] . Others have suggested that the action 
of GABA B  autoreceptors may involve G-protein interac-
tion with protein kinase C [37, 41] , protein kinase A [42] , 
or direct effects on the exocytotic machinery [43] , but we 
have no information on such possible mechanisms at 
present. 
 We now demonstrate that, in common with many oth-
er brain regions [9] , glutamate terminals in both deep 
and superficial layers of the EC bear inhibitory GABA B  
heteroreceptors, and that these receptors can suppress 
quantal, activity-independent glutamate release. We have 
 Fig. 5. Summary of the effects of presynaptic GABA B R activation 
on glutamate and GABA release in slices from epileptic rats.  a The 
reduction in frequency of mEPSCs was less in epileptic animals. 
This was the case at both concentrations and in both layer II and 
layer V, although only the difference at 10   M reached signifi-
cance.  b A very similar picture was seen with mIPSCs, with a re-
duced effect in both layers. Again, only the difference at 10   M 
was significant. Numbers of cells recorded are shown at the foot 
of the bars. 
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previously found that baclofen can substantially depress 
both sEPSC and mEPSC frequency in layer V neurones 
[M.O. Cunningham, PhD thesis, unpubl. results]. In the 
current study we found that two other potent GABA B R 
agonists, CGP44533 and CGP35024, also robustly de-
creased mEPSC frequency, with the latter drug being 
slightly more potent. GABA B R antagonists abolished the 
effects of CGP44533, and neither agonist had any effect 
on amplitude or kinetics of mEPSCs, so the results clear-
ly indicate that they were acting at presynaptic GABA B R 
to reduce glutamate release. As with the autoreceptor, this 
heteroreceptor control of glutamate release could be ex-
erted on activity-independent quantal events, but the 
precise mechanism requires further investigation. 
 There is an increasing body of evidence to indicate 
heterogeneity of GABA B  auto- and heteroreceptors [10–
14] . The reason for selecting CGP44533 as an agonist for 
use in our studies was because it has been suggested to be 
largely inactive at postsynaptic receptors [15] but to be 
selective for heteroreceptors over autoreceptors [14, 16] . 
Our studies do not directly support such a conclusion, 
although the situation was not straightforward. In terms 
of percentage change, the drug had a very similar effect 
at autoreceptors in layer II and layer V and also at hetero-
receptors in layer V. However, CGP44533 was consistent-
ly more effective in layer II, and induced a greater maxi-
mum depression of mEPSC frequency in this layer. This 
could suggest that the heteroreceptor in layer II is differ-
ent to that in layer V, and indeed to the autoreceptor in 
either layer. However, the EC 50  values for depression of 
mEPSC frequency were virtually identical in layer II and 
V, which more likely indicates that the receptor is the 
same in both layers, but that glutamate terminals in the 
superficial layer express a greater density of the receptor. 
It is also possible that the receptor is expressed at the same 
density, but is less efficiently coupled to the intracellular 
effector mechanism in layer V, or even coupled to a dif-
ferent effector. However, whilst the difference between 
layer II and V is interesting, it should be stressed that it is 
not dramatic, and our data do not strongly support het-
erogeneity of receptors on glutamate and/or GABA ter-
minals in the EC. 
 In a previous investigation [8] we reported that a 
 GABA B R antagonist, CGP55845, increased the frequency 
of mIPSCs in layer V (but not layer II) and we suggested 
that this resulted from blockade of tonic feedback activa-
tion of GABA B R, similar to that seen in other brain areas 
[36, 44] . However, mIPSC frequency in either layer was 
not significantly affected by GABA B R antagonists in the 
present study, although there were occasions where a 
clear increase was seen. It should be noted that the in-
crease in mIPSC frequency in layer V reported previous-
ly [8] occurred with very high concentrations of the an-
tagonist (10–50   M ). In the present study, lower concen-
trations of the antagonists failed to consistently alter 
mIPSC frequency, despite the fact that the same concen-
trations were able to abolish the decrease in frequency 
induced by GABA B R agonists. Thus, at present we are 
unsure if the effects of the high concentrations of 
CGP55845 [8] are the result of blockade of tonic feedback 
activation of the autoreceptors, or result from another, as 
yet undetermined, effect of the drug. 
 In the case of mEPSCs, again the antagonists had no 
significant effect on mEPSC frequency at concentrations 
where the effects of bath-applied agonists were abolished, 
suggesting that in our slices, GABA B  heteroreceptors 
were not normally tonically activated. Again, there were 
occasional instances where mEPSC frequency was clear-
ly increased, which could indicate that under some cir-
cumstances there is a tonic spillover of GABA to hetero-
receptors on glutamate terminals. However, in other 
studies [M.O. Cunningham and R.S.G. Jones, unpubl. re-
sults] we found that high concentrations of CGP55845 
actually decreased mEPSC frequency and amplitude in 
layer V, so again there may be other effects of the antago-
nists to consider that may not be related to GABA B R 
blockade. It should be remembered that our experiments 
were all conducted in TTX where ambient GABA release 
would be reduced. Also, in contrast to slices, a much 
higher baseline release of GABA probably occurs  in vivo, 
so tonic physiological activation of both auto- and hetero-
receptors may well occur. 
 The role of the EC in temporal lobe epilepsy has re-
ceived increasing attention in recent years, and there is 
strong clinical and experimental evidence to suggest a 
role in the initiation and propagation of seizures of tem-
poral lobe-limbic system origin  [ see 4 ] . Here, we demon-
strate that in a model of chronic temporal lobe seizures 
there is a decline in the depressant effects of presynaptic 
GABA B R on both glutamate and GABA release. The ef-
fect was further generalized in that both deep and super-
ficial layers of the EC were affected. A decline in GABA B  
autoreceptor function in CA1 and the dentate gyrus has 
previously been reported in electrical kindling models of 
temporal lobe epilepsy [20, 21] . Likewise, decreased het-
eroreceptor function has been described in the amygdala 
and hippocampus in kindling or pilocarpine-induced 
chronic seizure animals [22–24] , and there is an indica-
tion that both auto- and heteroreceptor function may be 
reduced in human neocortical tissue isolated from pa-
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tients with temporal lobe epilepsy [45] . However, it should 
be noted that Gloveli et al.  [25] have reported an  increased 
GABA B  autoreceptor function in layer III of the EC in 
electrically kindled rats. This was accompanied by an ap-
parent increase in immunocytochemical labeling of 
GABA B R across all layers of the EC, although this label-
ing does not distinguish between pre- and postsynaptic 
receptors. We have not yet studied either auto- or hetero-
receptor function in layer III in our pilocarpine-treated 
animals. It should be noted that layer III differs from the 
other layers of the EC to some extent, in that it shows pro-
nounced cell loss in both human epileptic patients and in 
animal models [46, 47] . Thus, we should not assume that 
the decrease in presynaptic GABA B R function we find in 
layers II and V would be mirrored by a similar effect in 
layer III, and this requires further study. 
 The question arises as to the significance of our results 
for the genesis and maintenance of the chronic seizures. 
It is difficult to relate the results of other studies that have 
looked at the expression of GABA B R in animal models 
and human epilepsy tissue to the functional studies dis-
cussed above and reported here. To start with, expression 
and immunocytochemical labeling studies do not distin-
guish between pre- and postsynaptic receptors. Exami-
nation of the literature reveals a bewildering array of 
changes, including both up- and down-regulation, which 
vary markedly depending on the model used, the area 
examined, the receptor subunits studied and the time 
point in the process of chronic seizure generation [25, 
48–53] . However, what is clear is that transgenic mice 
lacking functional GABA B R present epileptic phenotypes 
[17–19, 54] , and although the specific contribution of loss 
of      post-      or     presynaptic     auto/heteroreceptor     function    
 in these phenotypes is unclear, it seems certain that 
 GABA B R control helps to prevent hypersynchrony in 
cortical networks. 
 Clearly, both excitation and inhibition are subject to 
such control in the EC. It could be argued that the effects 
we observe on mPSCs may be less important than effects 
on action potential driven release in terms of epileptogen-
esis. However, there is no reason to presume a priori that 
quantal release of glutamate and GABA are unimportant 
in   control   of   network   excitability.   In   fact,   the   majority 
of    spontaneous    release    of    both    transmitters   in   the   EC  
 is TTX-insensitive [1, 4, 7]. In any case, the reduced 
 GABA B R-mediated control of quantal release that we see 
mirrors the changes reported elsewhere for control of ac-
tion potential-dependent release [20–25] . Thus, whatever 
the effector mechanisms involved, impaired GABA B R 
function would be felt by both forms of release in the in-
tact epileptic brain. The loss of inhibitory control of glu-
tamate release could result in enhanced excitatory trans-
mission and increased network excitability leading to ep-
ileptogenesis. It is more difficult to see how the reduced 
autoreceptor control of GABA release may fit in. One 
possibility is that this is an adaptive change occurring in 
response to the epileptogenic state, designed to increase 
inhibition across the network and reduce the propensity 
to synchronization. However, GABA interneurones are 
increasingly being viewed as drivers of network synchro-
ny [55–57] , and that pathological changes in interneu-
rone driven synchronization of principal neurones [58] 
and excitatory actions of GABA [59] could be underlying 
factors in epilepsy. Thus, a loss of feedback autoreceptor 
control of inhibition could be a destabilizing factor in 
network excitability, exacerbated by the concurrent loss 
of inhibitory control of glutamate release. If GABA A  re-
ceptor-mediated depolarizing events contribute to epi-
leptogenesis, then increased GABA release consequent 
upon decreased GABA B  autoreceptor function could ex-
acerbate this effect [59–61] . However, at present we do not 
know whether the reduced effectiveness of presynaptic 
GABA B R is a causal factor in chronic epilepsy or casu-
ally related to it. An important next step will be to deter-
mine the time course of changes in these presynaptic re-
ceptors in relationship to the development of the chronic 
recurring seizures. 
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